Amedeo Smart

Free Medical Literature Service


 

Amedeo

Influenza

  Free Subscription

Articles published in
Drugs
    June 2022
  1. KEAM SJ
    Tixagevimab + Cilgavimab: First Approval.
    Drugs. 2022;82:1001-1010.
    >> Share

  2. KOUFAKIS T, Mustafa OG, Ajjan RA, Garcia-Moll X, et al
    From Skepticism to Hope: The Evolving Concept of the Initiation and Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients.
    Drugs. 2022;82:949-955.
    >> Share

    March 2022
  3. LAMB YN
    Nirmatrelvir Plus Ritonavir: First Approval.
    Drugs. 2022 Mar 19. pii: 10.1007/s40265-022-01692.
    >> Share

  4. HEO YA
    Sotrovimab: First Approval.
    Drugs. 2022;82:477-484.
    >> Share

  5. SYED YY
    Molnupiravir: First Approval.
    Drugs. 2022;82:455-460.
    >> Share

    February 2022
  6. MAZZA MG, Vai B, De Picker L, Benedetti F, et al
    Comment on: "Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence".
    Drugs. 2022;82:349-351.
    >> Share

  7. LENZE EJ, Reiersen AM, Facente SN
    Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARSCoV2 Infection: A Review of Current Evidence".
    Drugs. 2022;82:353-354.
    >> Share

    January 2022
  8. RIZK JG, Wenziger C, Tran D, Hashemi L, et al
    Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19.
    Drugs. 2022;82:43-54.
    >> Share

    December 2021
  9. FACENTE SN, Reiersen AM, Lenze EJ, Boulware DR, et al
    Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.
    Drugs. 2021;81:2081-2089.
    >> Share

  10. SYED YY
    Regdanvimab: First Approval.
    Drugs. 2021;81:2133-2137.
    >> Share

    November 2021
  11. DEEKS ED
    Casirivimab/Imdevimab: First Approval.
    Drugs. 2021;81:2047-2055.
    >> Share

    September 2021
  12. AHMED N, Pezacki JP
    Reply to Zhang and Zhu "MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19".
    Drugs. 2021;81:1693-1695.
    >> Share

  13. ZHANG S, Zhu F
    Comment on: "MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19".
    Drugs. 2021;81:1691-1692.
    >> Share

    July 2021
  14. ROE MT, Patrick-Lake B, von Eschenbach AC
    Post-COVID-19 Syndrome: Leveraging the Patient Perspective and Technological Innovations to Enable the Delineation of Effective Treatments.
    Drugs. 2021;81:1235-1237.
    >> Share

    June 2021
  15. VUORIO A, Kovanen PT
    Comment on: "Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry".
    Drugs. 2021;81:1125-1127.
    >> Share

    April 2021
  16. HEO YA
    Voclosporin: First Approval.
    Drugs. 2021;81:605-610.
    >> Share

  17. HUM C, Loiselle J, Ahmed N, Shaw TA, et al
    MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19.
    Drugs. 2021;81:517-531.
    >> Share

  18. TORRES-PENA JD, Perez-Belmonte LM, Fuentes-Jimenez F, Lopez Carmona MD, et al
    Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry.
    Drugs. 2021;81:685-695.
    >> Share

    March 2021
  19. LAMB YN
    BNT162b2 mRNA COVID-19 Vaccine: First Approval.
    Drugs. 2021;81:495-501.
    >> Share

    December 2020
  20. LIN KJ, Schneeweiss S, Tesfaye H, D'Andrea E, et al
    Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity.
    Drugs. 2020;80:1961-1972.
    >> Share

    October 2020
  21. CANTINI F, Goletti D, Petrone L, Najafi Fard S, et al
    Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.
    Drugs. 2020 Oct 17. pii: 10.1007/s40265-020-01421.
    >> Share

  22. HAJRA A, Mathai SV, Ball S, Bandyopadhyay D, et al
    Management of Thrombotic Complications in COVID-19: An Update.
    Drugs. 2020;80:1553-1562.
    >> Share

    September 2020
  23. LAMB YN
    Remdesivir: First Approval.
    Drugs. 2020;80:1355-1363.
    >> Share

  24. RIZK JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, et al
    Pharmaco-Immunomodulatory Therapy in COVID-19.
    Drugs. 2020;80:1267-1292.
    >> Share

  25. VRACHATIS DA, Giotaki SG, Giannopoulos G, Deftereos S, et al
    Comment on: "Pharmaco-Immunomodulatory Therapy in COVID-19".
    Drugs. 2020;80:1499-1500.
    >> Share

  26. RIZK JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, et al
    Authors' Reply to Vrachatis et al. "Pharmaco-Immunomodulatory Therapy I COVID-19".
    Drugs. 2020;80:1501-1503.
    >> Share

  27. BIANCONI V, Violi F, Fallarino F, Pignatelli P, et al
    Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?
    Drugs. 2020;80:1383-1396.
    >> Share

    July 2020
  28. PANERA N, Tozzi AE, Alisi A
    The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19.
    Drugs. 2020;80:941-946.
    >> Share

    June 2020
  29. SHIRLEY M
    Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza.
    Drugs. 2020 Jun 29. pii: 10.1007/s40265-020-01350.
    >> Share

    November 2019
  30. LAMB YN
    Correction to: Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax((R)) Tetra/Flucelvax Quadrivalent((R))): A Review in the Prevention of Influenza.
    Drugs. 2019 Nov 25. pii: 10.1007/s40265-019-01237.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016